You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Prescient said the acquisition will expand its lab capabilities and enhance its relationships with local, regional, and national health insurers.
NEW YORK (GenomeWeb) – PGXL Technologies today said that it has formed a partnership with NX PharmaGen under which the partners have created a research center focused on exosome analysis.
NEW YORK (GenomeWeb) – PGXL Laboratories has received licensure from California to provide its testing services in the state.
NEW YORK (GenomeWeb News) – Pharmacogenetic testing firm PGXL Laboratories announced on Thursday a long-term national distribution deal with Essential Molecular Testing for PGXL's drug sensitivity testing.
This article has been updated to include information about a competing product in the market.
PGXL, a Louisville, Ky.-based pharmacogenomics services provider, plans to introduce other AutoGenomics assays, such as its KRAS-BRAF test, in the future.
Starting next month, PGXL and Generation Health will provide pharmacogenetic testing and diagnostic services to patients through healthcare providers.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.